Cabozantinib added to chemotherapy for new osteosarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding cabozantinib to standard chemotherapy works better in children and young adults with newly diagnosed high-grade osteosarcoma. It may help by improving control of the cancer, especially for higher-risk cases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be under 40 years old when you start the study.
- Your body size must meet a minimum (body surface area at least 0.8 m²).
- Your osteosarcoma must be newly diagnosed and confirmed as high-grade by pathology.
- Your cancer spread must fit the trial’s definition (lungs or certain bone spots), or you may qualify even if it is localized for the appropriate risk group.
- You need enough blood counts and organ function (kidney, liver, heart) based on recent lab tests and heart tests.
- You must be able to swallow tablets whole, and you must not have had prior chemotherapy or prior systemic cancer treatment for osteosarcoma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a combination of two medicines—atezolizumab and cabozantinib—for teenagers and young adults with osteosarcoma that has come back or spread. It aims to slow or shrink the cancer and help control disease that can’t be fully removed with surgery.
This trial studies cabozantinib given after standard treatment to try to keep high-risk pediatric solid tumors from coming back or getting worse. It is offered to children and young adults whose cancer has not fully disappeared but is not progressing at the start of this maintenance phase.
This trial tests a new drug called tegavivint combined with the chemotherapy drug gemcitabine for people whose osteosarcoma has come back or stopped responding to treatment. The goal is to see if this combination can help shrink or control the cancer.
This study tests a combination of two drugs, cabozantinib and ifosfamide, for sarcomas that have come back or not responded to treatment. The goal is to see if this combination can help shrink or control the cancer.
This Phase 2 trial studies whether combining pembrolizumab and cabozantinib can control advanced sarcoma that can’t be removed by surgery and has grown or returned after standard treatment. It may help shrink tumors and improve outcomes in adults who have limited treatment options left.
This research study follows young people newly diagnosed with osteosarcoma (a type of bone cancer) who are receiving standard chemotherapy. Researchers will collect information about how the cancer responds to treatment and study biological samples to better understand the disease.
Hear when a new Metastatic Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.